Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal Zacks Investment Research - Tue Oct 8, 11:00AM CDT

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 45.54 (+0.29%)
ANIP : 55.38 (+0.24%)
CPRX : 21.19 (+1.78%)
SRRK : 26.64 (+0.99%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal Zacks Investment Research - Tue Sep 24, 10:58AM CDT

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 45.54 (+0.29%)
KRYS : 177.54 (+1.08%)
FULC : 2.91 (-3.96%)
ANIP : 55.38 (+0.24%)
Author
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? MarketBeat - Tue Sep 24, 9:42AM CDT

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

BHVN : 45.54 (+0.29%)
Canada Jobs in Focus Next Week Baystreet - Fri May 3, 4:47PM CDT

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

VRTX : 456.57 (-2.24%)
MCHP : 63.97 (-1.96%)
PLTR : 62.25 (+1.62%)
DIS : 111.80 (-1.53%)
ANET : 377.71 (+1.95%)
TM : 175.64 (+0.49%)
UBER : 68.99 (-0.49%)
ABNB : 131.50 (-0.52%)
HMC : 26.68 (+0.60%)
CEG : 231.55 (+0.55%)
RBLX : 52.33 (+2.55%)
BHVN : 45.54 (+0.29%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® PR Newswire - Mon Oct 16, 2023

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 45.54 (+0.29%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 45.54 (+0.29%)
Wall Street - NYSE Full View
Markets Today: Stocks Decline as Bond Yields Soar Barchart - Tue Oct 3, 2023

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESZ24 : 5,929.00 (+0.15%)
NQZ24 : 20,694.50 (+0.30%)
MCK : 616.19 (+0.10%)
BHVN : 45.54 (+0.29%)
ABNB : 131.50 (-0.52%)
KLG : 17.14 (+0.29%)
HPQ : 37.11 (-0.85%)
DOW : 43.51 (-1.61%)
LYB : 82.59 (-0.73%)
FVRR : 30.12 (+1.04%)
DY : 199.43 (+1.84%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 45.54 (+0.29%)
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 45.54 (+0.29%)
Why Biohaven Stock Is Skyrocketing Today Motley Fool - Wed Sep 27, 2023

Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain.

BHVN : 45.54 (+0.29%)

Barchart Exclusives

Meta Platforms - Massive FCF Gusher - Shorting OTM Puts Works Best Barchart - 36 minutes ago
Meta Platforms stock looks cheap here as a huge free cash flow generator. Moreover, shorting put options expiring in two weeks with out-of-the-money (OTM) strike prices yields 1.2% - i.e., set a buy-in price and get paid while waiting. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot